RFP-Based Independent Medical Education Grants
Alnylam Pharmaceuticals funds independent educational initiatives advancing medical knowledge in rare diseases like ATTR amyloidosis, AHP, and PH1 through RFP-based grants.
Funder: Alnylam Pharmaceuticals
Due Dates: Rolling (RFPs posted throughout the year; submit at least 45 days before activity start)
Funding Amounts: Amount determined case-by-case per RFP; no public upper/lower limit specified.
Summary: Supports independent, evidence-based educational initiatives in rare diseases (ATTR amyloidosis, AHP, PH1) through responses to targeted RFPs.
Description
Alnylam Pharmaceuticals, through its Grants and Giving Office, offers independent medical education grants in response to specific Requests for Proposals (RFPs) posted throughout the year. These grants support independently designed and executed educational initiatives that advance scientific, clinical, and medical knowledge in rare diseases, specifically transthyretin-mediated amyloidosis (ATTR amyloidosis), acute hepatic porphyria (AHP), and primary hyperoxaluria type 1 (PH1). The goal is to improve patient outcomes by supporting evidence-based, clinically relevant programs for healthcare professionals, patients, or the broader healthcare community. Grantee organizations retain full independence over content and execution, with a requirement for transparent acknowledgment of Alnylam’s support and strict compliance with all regulatory guidelines.
